All right, I want to start off with some of the news of this morning. We're seeing oil prices move higher on sanctions on Venezuela and also potential sanctions on Russia. Uh, does this idea of the potential for oil to move higher, at least we're seeing that move this morning, does it change your view of any sectors or the markets in general.>> Sure. Look, I mean, oil prices has so far not contributed to the inflation pressures in the US, which obviously helped the Fed cut rates. This is a key indicator tha ...

Core Insights - The State Street SPDR S&P Biotech ETF (XBI) is a passively managed ETF launched on January 31, 2006, designed to provide broad exposure to the Healthcare - Biotech segment of the equity market [1] - The ETF has gained popularity among retail and institutional investors due to its low costs, transparency, flexibility, and tax efficiency [1][2] - As of now, the fund has amassed over $7.82 billion in assets, making it one of the largest ETFs in the Healthcare - Biotech sector [3] Index and Performance - XBI seeks to match the performance of the S&P Biotechnology Select Industry Index, which represents the biotechnology sub-industry portion of the S&P Total Markets Index [4] - The ETF has shown a performance increase of approximately 35.52% over the past year and about 28.8% year-to-date [8] - The ETF has a beta of 0.87 and a standard deviation of 26.86% over the trailing three-year period, indicating a high-risk profile [8] Costs and Holdings - The annual operating expense ratio for XBI is 0.35%, making it one of the least expensive options in the ETF space [5] - The ETF has a 12-month trailing dividend yield of 0.03% [5] - The fund is fully allocated to the Healthcare sector, with Crispr Therapeutics Ag (CRSP) accounting for about 2.48% of total assets, and the top 10 holdings representing approximately 19.54% of total assets [6][7] Alternatives - XBI carries a Zacks ETF Rank of 3 (Hold), indicating it is a sufficient option for investors seeking exposure to the Health Care ETFs area [9] - Other ETF options in the space include First Trust NYSE Arca Biotechnology ETF (FBT) with $1.35 billion in assets and iShares Biotechnology ETF (IBB) with $8.60 billion in assets, both having higher expense ratios than XBI [10]

Core Viewpoint - Needham analyst David Saxon has raised the price target for SI-Bone (SIBN) to $27 from $24 while maintaining a Buy rating on the shares, indicating confidence in the company's growth potential [1] Group 1: Price Target and Ratings - The price target for SI-Bone has been increased to $27 from $24 [1] - SI-Bone has been added to Needham's 'Conviction List' and is named as the firm's '2026 Top Pick' [1] Group 2: Growth Potential - Needham believes SI-Bone can deliver potential upside to estimates in the near term, which is expected to enhance profitability [1] - Upcoming product launches are anticipated to drive active surgeon adoption across SI-Bone's portfolio, leading to higher utilization [1]

Stifel raised the firm’s price target on Landstar System (LSTR) to $140 from $127 and keeps a Hold rating on the shares. For 2026, the firm believes the focus for transport stocks will be on supply rationalization and cost-driven self-help, says the analyst, who continues to position “more conservatively in high-quality names that preserve or even expand share in a mild pullback.” Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designe ...

Stifel raised the firm’s price target on Old Dominion (ODFL) to $173 from $160 and keeps a Buy rating on the shares. For 2026, the firm believes the focus for transport stocks will be on supply rationalization and cost-driven self-help, says the analyst, who continues to position “more conservatively in high-quality names that preserve or even expand share in a mild pullback.” Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to ...

Stifel analyst J. Bruce Chan raised the firm’s price target on Proficient Auto Logistics (PAL) to $12 from $11 and keeps a Buy rating on the shares. For 2026, the firm believes the focus for transport stocks will be on supply rationalization and cost-driven self-help, says the analyst, who continues to position “more conservatively in high-quality names that preserve or even expand share in a mild pullback.” Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powe ...

Stifel raised the firm’s price target on RXO Inc. (RXO) to $16 from $15 and keeps a Hold rating on the shares. For 2026, the firm believes the focus for transport stocks will be on supply rationalization and cost-driven self-help, says the analyst, who continues to position “more conservatively in high-quality names that preserve or even expand share in a mild pullback.” Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help ...

Swiss financial giant UBS said on Wednesday it had hired a senior executive from Britain's Legal & General (L&G) to co-head an expanded $1.8 trillion direct investments unit. ...

JUPITER, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications, diverse commercial applications, today announced a significant expansion of its collaboration with Fermbox Bio, a biotech research & manufacturing company developing and delivering sustainable bio-based pr ...

NEW YORK (AP) — Warner Bros. is telling shareholders to reject a takeover bid from Paramount Skydance, saying that a rival bid from Netflix will be better for customers. “We strongly believe that Netflix and Warner Bros. joining forces will offer consumers more choice and value, allow the creative community to reach even more audiences with our combined distribution, and fuel our long-term growth,” Warner Bros. said Wednesday. “We made this deal because their deep portfolio of iconic franchises, expansive ...